A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
← catalyst calendarNCT07214870 · readout in 267 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
60estimated
Sites
1
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-08 | actual | When the study began enrolling |
| Primary completion | 2027-05-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-14 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Fatty Liver Disease
Interventions
- Drug: NNC4005-001
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Treatment-emergent adverse event (TEAEs)
measured From dosing (day 1) until compeletion of end of study (EOS) visit on day 169
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed